What are the causes of an elevated 17‑hydroxyprogesterone (17‑OHP) level?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Causes of Elevated 17-Hydroxyprogesterone (17-OHP) Levels

The most common cause of elevated 17-OHP is 21-hydroxylase deficiency (accounting for ~95% of congenital adrenal hyperplasia cases), but you must also consider 11-hydroxylase deficiency, P450 oxidoreductase deficiency, 3β-hydroxysteroid dehydrogenase deficiency, and hormone-secreting adrenal or ovarian tumors 1.

Primary Causes by Category

Enzymatic Deficiencies (Most Common)

21-Hydroxylase Deficiency (Congenital Adrenal Hyperplasia)

  • Represents approximately 95% of CAH cases 1
  • Results from mutations in CYP21A2 gene encoding steroid 21-hydroxylase enzyme
  • The enzyme normally converts 17-OHP to 11-deoxycortisol; deficiency causes 17-OHP accumulation
  • Three clinical forms exist:
    • Classic salt-wasting CAH (~75% of classic cases): Baseline 17-OHP typically >300 nmol/L (>10,000 ng/dL) 1
    • Classic simple virilizing CAH: Similar 17-OHP elevation without aldosterone deficiency
    • Nonclassic CAH (NCCAH): Baseline 17-OHP 6-300 nmol/L (200-10,000 ng/dL); post-ACTH stimulation 31-300 nmol/L (1,000-10,000 ng/dL) 1

Other Enzymatic Defects

  • 11-hydroxylase deficiency: Also causes 17-OHP elevation and must be differentiated from 21-hydroxylase deficiency 1
  • P450 oxidoreductase deficiency: Can present with elevated 17-OHP 1
  • 3β-hydroxysteroid dehydrogenase deficiency: Extremely rare but can cause elevated 17-OHP in newborn screening despite absence of virilization 2

Tumor-Related Causes (Critical to Exclude)

Adrenal Tumors

  • 17-OHP-secreting adrenal cortical adenomas: Can mimic NCCAH biochemically 3, 4, 5
  • May show positive ACTH stimulation test responses similar to 21-hydroxylase deficiency 4, 6
  • Consider when DHEAS >600 µg/dL (16,000 nmol/L), which suggests adrenal source 7
  • Adrenal venous sampling can confirm lateralization of 17-OHP hypersecretion 5
  • Unique presentation: Autoimmune adrenalitis with concurrent adrenal adenoma can cause elevated 17-OHP due to chronic ACTH stimulation unmasking low 21-hydroxylase expression in the tumor 3

Ovarian Tumors

  • Steroid cell tumors, not otherwise specified (SCT-NOS): Can secrete 17-OHP 6
  • Ovarian hyperthecosis: Associated with markedly elevated testosterone (>2× upper normal limit) and insulin resistance 7
  • Urinary steroid profile can help localize 17-OHP source to ovaries versus adrenals 6

Diagnostic Algorithm

Initial Evaluation

  1. Obtain early morning baseline serum 17-OHP in symptomatic individuals 1
  2. Interpret baseline levels:
    • 300 nmol/L (>10,000 ng/dL): Likely classic CAH

    • 6-300 nmol/L (200-10,000 ng/dL): Likely NCCAH or tumor
    • <6 nmol/L (<200 ng/dL): Likely unaffected or heterozygote 1

Confirmatory Testing

  1. Perform cosyntropin stimulation test with complete adrenocortical profile to differentiate enzyme defects and diagnose borderline cases 1
    • Post-ACTH 17-OHP >300 nmol/L (>10,000 ng/dL): Classic CAH
    • Post-ACTH 17-OHP 31-300 nmol/L (1,000-10,000 ng/dL): Likely NCCAH
    • Post-ACTH 17-OHP <50 nmol/L (<1,666 ng/dL): Unaffected or heterozygote 1

Additional Workup When Indicated

  1. Measure DHEAS if testosterone is >2× upper normal limit 7
    • DHEAS >600 µg/dL suggests adrenal tumor; obtain abdominal imaging urgently
  2. Check other steroids: 21-deoxycortisol, androstenedione, testosterone 1
  3. Assess aldosterone synthesis: Plasma renin activity and aldosterone-to-PRA ratio to differentiate salt-wasters from simple virilizers 1

When Tumor is Suspected

  1. Obtain imaging:
    • Abdominal CT for adrenal masses 4
    • Transvaginal ultrasound and FDG PET-CT for ovarian tumors 6
  2. Consider urinary steroid profile to localize 17-OHP source (ovarian vs. adrenal) 6
  3. Adrenal venous sampling may be needed to confirm lateralization in adrenal adenomas 5

Genetic Testing

  1. Reserve genotyping for equivocal cosyntropin test results or genetic counseling purposes 1
    • Poor response to dexamethasone suppression in presumed NCCAH warrants gene mutation analysis 4

Critical Pitfalls to Avoid

  • Don't assume all elevated 17-OHP is CAH: Tumors can mimic NCCAH biochemically, including positive ACTH stimulation responses 4, 6
  • Don't overlook rare enzyme defects: 3β-hydroxysteroid dehydrogenase deficiency can present with elevated 17-OHP but without expected virilization 2
  • Consider timing and medications: Assay conditions matter—check cycle timing, avoid thyroid hormones or estrogenic drugs that affect SHBG 7
  • Heterozygotes can have mildly elevated 17-OHP after ACTH stimulation with overlap to unaffected subjects 1
  • In women with infertility and elevated 17-OHP: If genetic testing is negative for 21-hydroxylase deficiency and steroid suppression fails, obtain imaging to exclude hormone-secreting tumors 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.